Trial Profile
Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 15 Sep 2022
Price :
$35
*
At a glance
- Drugs Nicotinamide (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Amina-X-002
- 09 Aug 2022 Primary endpoint has not been met (Hazard ratio (PFS) of the nicotinamide arm to the placebo arm) , according to Results presented at the 2022 World Conference on Lung Cancer
- 09 Aug 2022 Results reporting OS, PFS and safety data presented at the 2022 World Conference on Lung Cancer
- 25 Nov 2018 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020.